Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
Svenja Petersohn, Gilles Salles, Michael Wang, Jim Wu, Sally W. Wade, Claire L. Simons, Craig Bennison, Rubina Siddiqi, Weimin Peng, Ioana Kloos, Gab Castaigne, Georg Hess
Dive into the research topics of 'Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England'. Together they form a unique fingerprint.